PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy

SIMPLE SUMMARY: Prostate-specific membrane antigen (PSMA) is a promising target for both imaging and radioligand therapies (RLT) for men with prostate cancer. However, not all patients respond to RLT and some even progress early in the treatment course. We aimed to identify parameters to forecast wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Widjaja, Liam, Werner, Rudolf A., Ross, Tobias L., Bengel, Frank M., Derlin, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230748/
https://www.ncbi.nlm.nih.gov/pubmed/34208246
http://dx.doi.org/10.3390/cancers13122938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230748/
https://www.ncbi.nlm.nih.gov/pubmed/34208246
http://dx.doi.org/10.3390/cancers13122938

Ejemplares similares